Self.co Secures €2.56M to Expand Access to Molecular Allergy Testing

Self.co, a digital health startup focused on allergy and food intolerance management, has successfully raised €2.56 million through a combination of grants and venture capital. This new funding will support the company's mission to make advanced molecular allergy testing more accessible to a wider audience, empowering individuals with better tools for understanding and managing their allergic conditions.